CXCR3/CXCL10 ANTAGONISTIC COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING BONE METASTASIS

摘要

The present invention relates to a pharmaceutical composition for preventing and treating bone metabolic diseases according to the bone metastasis of cancer cells, wherein JN-2 and ION35 which are synthesized products of chemokine ligand 10 (CXCL10) are competitively combined with the acceptor (CXCR3) of the chemokine ligand 10 (CXCL10). The chemokine ligand 10 (CXCL10) increased by the bone metastasis of cancer cells acts in osteoblasts, so that the expression of RANKL which is an important factor for the differentiation of osteoblasts is increased and the differentiation of the osteoblasts is induced, according to a prior research result. Based on the prior research result, breast cancer cells (4T1) which can be easily transferred to bone cancer cells are directly administrated into the shinbone of a mouse and the composition of the present invention is administrated into the abdominal cavity for a particular period of time. As a result, resistance against bone remodeling due to the cancer cells settled in the bones is inhibited, so that bone destruction caused by the therapeutically transferred cancer cells and metabolic diseases can be controlled and treated through the same.;COPYRIGHT KIPO 2014